Genetics and new treatment modalities for familial Mediterranean fever

Research output: Chapter in Book/Report/Conference proceedingConference contribution

34 Scopus citations


Familial Mediterranean fever (FMF) is the most common of a rare group of disorders collectively termed familial hereditary periodic fever syndromes, also known as autoinflammatory syndromes. FMF is clinically characterized by intermittent bouts of fever with peritonitis and abdominal pain, pleuritis, arthritis, or erysipelas-like rashes. Amyloidosis due to chronic inflammation progressing to renal failure is one of the most serious potential complications of this disease. Individuals with FMF have identifiable genetic defects in the Mediterranean fever (MEFV) gene, which codes for the protein pyrin. Pyrin normally blunts neutrophil-mediated inflammation, likely via interleukin-1 (IL-1) downregulation, but is defective in FMF. Potential treatments include colchicine, with case reports of benefits with catecholamine blockade (prazosin), tumor necrosis factor (TNF) antagonism (etanercept, thalidomide), and IL-1 receptor blockade (anakinra).

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Number of pages8
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)00778923
ISSN (Electronic)17496632


  • Amyloidosis
  • Colchicine
  • Familial Mediterranean fever
  • Interferon α
  • Pyrin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Genetics and new treatment modalities for familial Mediterranean fever'. Together they form a unique fingerprint.

Cite this